<DOC>
	<DOCNO>NCT00104052</DOCNO>
	<brief_summary>The primary objective ass safety , efficacy tolerability combination PEG-Intron plus REBETOL pediatric subject chronic hepatitis C. The secondary objective measure multiple-dose pharmacokinetics PEG-Intron REBETOL pediatric subject chronic hepatitis C .</brief_summary>
	<brief_title>Study PEG-Intron Plus REBETOL Pediatric Subjects With Chronic Hepatitis C ( Study P02538 Part 1 )</brief_title>
	<detailed_description>This global , multicenter , open-label Phase 3 study evaluate safety , efficacy tolerability PEG-Intron plus REBETOL previously untreated pediatric subject , age 3 17 year , chronic hepatitis C .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Children age 317 year old Individuals weigh ≤ 90 kg Previously untreated child chronic hepatitis C ( HCV RNA qPCR plasma positive ) Individuals HCV ( hepatitis C virus ) genotype Hematology laboratory result : Hemoglobin ( HGB ) ≥ 11 g/dL female ≥ 12g/dL male , White Blood Cell Count ( WBC ) ≥ 3,000/mm^3 , Neutrophils ≥ 1,500/mm^3 , Platelets ≥ 100,000/mm^3 Chemistry laboratory result : Normal Thyroid Stimulating Hormone ( TSH ) , albumin , creatinine , Bilirubin , Antinuclear antibody ( ANA ) ≤ 1:160 , Fasting Glucose 70140 mg/dL . Note : If glucose level 116140 mg/dL individual diabetes , HbA1C must ≤ 8.5 % Compensated liver disease Historic pretreatment liver biopsy slide available No significant coexist psychiatric disease Those diabetes , hypertension , birth prior 32 week gestational age must normal eye exams retinal photograph ( do part study hepatitis C treatment give ) Patients partner patient willing use adequate contraception course study Abstain alcohol illicit drug Serum ALT &gt; 10 time upper limit normal within 6 month prior study Previous hepatitis C treatment Children liver disease cause hepatitis C Most recent liver biopsy normal Individuals infect hepatitis B virus and/or human immunodeficiency virus ( HIV ) Known blood disorder hemoglobinopathy , coagulopathy , G6PD deficiency Known immunodeficiency disorder require immunoglobulin therapy Body organ transplant Any known suspect cancer within past 5 year Children chronic pulmonary disease Individuals medical condition would likely require systemic steroid Those history central nervous system ( CNS ) trauma seizure disorder Individuals preexist psychiatric disorder include limited moderate severe depression Current previous use lithium antipsychotic drug Patients clinically significant electrocardiogram ( ECG ) abnormalities and/or significant cardiovascular dysfunction ( e.g. , angina , congestive heart failure , recent myocardial infarction , uncontrolled hypertension , significant arrhythmia , cardiac sequela Kawasaki disease , cardiomyopathy , and/or history congenital heart disease ) Insulindependent diabetes mellitus poorly control noninsulin dependent diabetes mellitus Immunologically mediate disease ( e.g. , inflammatory bowel disease [ Crohn 's disease , ulcerative colitis ] , rheumatoid arthritis , idiopathic thrombocytopenic purpura , systemic lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis , symptomatic thyroid disorder ) History substance abuse , include alcohol ( e.g. , binge drinking , blackout ) , intravenous drug inhale drug Subjects history pregnancy pregnant and/or breast feeding . Subjects intend become pregnant study period . Subjects partner intend become pregnant study period Subjects clinically significant retinal abnormality know retinopathy prematurity retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>